Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
TGTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$21.11 - $46.48
Previous CloseN/A
Volume723.16K
Average Volume (3M)2.53M
Market Cap
$4.72B
Enterprise Value$5.85B
Total Cash (Recent Filing)$276.24M
Total Debt (Recent Filing)$254.58M
Price to Earnings (P/E)84.7
Beta1.31
Next Earnings
Oct 30, 2025EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding158,665,620
10 Day Avg. Volume1,831,387
30 Day Avg. Volume2,531,133
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)19.67
Price to Sales (P/S)13.29
P/FCF Ratio-107.84
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue15.15
Enterprise Value/Gross Profit17.32
Enterprise Value/Ebitda83.54
Forecast
1Y Price Target
$32.67Price Target Upside2.45% Upside
Rating ConsensusHold
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Market PenetrationThe company described seeing a meaningful increase in new prescribers and accounts, representing deeper penetration across both the academic and community treatment settings.
Revenue GrowthBriumvi is now commercially available in additional countries in the EU, UK, Switzerland, and Australia, which could translate into incrementally larger royalty revenue in the quarters ahead.
Bears Say
Competitive ChallengesTG’s subq option is behind relative to approved subq options and may ultimately face an uphill battle in what is viewed as a growing section of the MS population.
Prescription TrendsThis is the first time repeat prescriptions have surpassed new prescriptions, potentially indicating a slowdown in new start growth.
TG Therapeutics News
TGTX FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $21.11 and its highest was $46.48 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $4.72B.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is in 54 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on Aug 04, 2025. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.211 by -$0.041.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.22.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 158,665,620 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $0.17 in its last earnings report, missing expectations of $0.211. Following the earnings report the stock price went down -17.99%.
Which hedge fund is a major shareholder of TG Therapeutics?
Currently, no hedge funds are holding shares in TGTX
TG Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$32.67 (2.45% Upside)
$32.67 (2.45% Upside)
Blogger Sentiment
Bullish
TGTX Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 160.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $369.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.24%
12-Months-Change
Fundamentals
Return on Equity
26.63%
Trailing 12-Months
Asset Growth
75.12%
Trailing 12-Months
Company Description
TG Therapeutics
TG Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative treatments for B-cell malignancies and autoimmune diseases. The company operates primarily in the biotechnology sector, focusing on targeted therapies that aim to improve patient outcomes. TG Therapeutics is known for its core products, including U2, an investigational treatment for chronic lymphocytic leukemia (CLL) and other hematologic malignancies, and TGR-1202, a selective inhibitor of PI3K delta, which is also in development for various cancers.
TGTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong quarter for TG Therapeutics, marked by significant revenue growth, successful product adoption, and strategic pipeline advancements. However, increased operating expenses and potential market challenges are areas of concern.View all TGTX earnings summariesTGTX Stock 12 Month Forecast
Average Price Target
$32.67
▲(2.45% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Nuvalent
―
Ownership Overview
9.81% Insiders
17.88% Mutual Funds
10.41% Other Institutional Investors
38.99% Public Companies and Individual Investors